Dermata Therapeutics Inc (DRMA) Sector
Health Care

(Current) $3.10
-0.04 (-1.27%) Open Price: 3.13

 

Dermata Therapeutics, Inc. was a clinical-stage biopharmaceutical company that focused on developing and commercializing innovative products for the treatment of dermatological conditions. The company was founded in 2010 and was based in San Diego, California.

 

The primary focus of Dermata Therapeutics was the development of a topical treatment for psoriasis, which is a chronic autoimmune disorder that affects the skin. The company's lead product candidate was a novel topical formulation of a well-known active ingredient that had been shown to be effective in treating psoriasis.

 

In addition to its lead product candidate, Dermata Therapeutics also had several other product candidates in its pipeline. These included treatments for atopic dermatitis, rosacea, and acne.

 

Dermata Therapeutics had established collaborations with several academic institutions and research organizations to support the development of its product candidates. The company had also received funding from the National Institutes of Health (NIH) to support the development of its psoriasis treatment.

 

In 2018, Dermata Therapeutics was acquired by Roivant Sciences, a global biopharmaceutical company that focuses on developing and commercializing innovative therapies. The acquisition allowed Roivant Sciences to expand its pipeline of dermatology-focused products and leverage Dermata Therapeutics' expertise in the development of topical treatments for skin diseases.

 

 

 

(06/11/24) $3.13
(06/12/24) $3.14
(06/12/24) (Qty.)1,725
(06/11/24) $3.12
(06/11/24) $3.31
(06/09/24) $3.07
(05/26/24) $3.92
Stocktwits
LetsEncrypt SSL Secure Stripe Payment Processing